CERo Therapeutics raises ~$1.25M via Series C preferred stock and warrant private placement

CERO THERAPEUTICS HOLDINGS, INC.

Filed Certificate of Designations for Series C Convertible Preferred Stock on Sept 25, 2024.
Issued 2,853 shares of Series C preferred and warrants for 8,175,166 common shares.
Gross proceeds of ~$1.25M from private placement with accredited investors.
Private placement closed on September 26, 2024.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC.: Filed Certificate of Designations creating Series C Convertible Preferred Stock (effective 2024-09-25).

Change: charter amendment
Effective: 2024-09-25

Exact text from the filing

On September 25, 2024, CERo Therapeutics Holdings, Inc. (the “ Company ”) filed a Certificate of Designations of Series C Convertible Preferred Stock with the Secretary of State of the State of Delaware (the “ Certificate of Designations ”), thereby creating a new series of preferred stock of the Company designated as “Series C Convertible Preferred Stock.”

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-24-084200

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.